Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kamil Wawrowicz has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploration of simultaneous dual-isotope imaging with multiphoton modular J-PET scanner

    by Ermias Y. Beyene, Manish Das, Martyna Durak-Kozica, Grzegorz Korcyl, Wiktor Mryka, Szymon Niedźwiecki, Szymon Parzych, Keyvan Tayefi, Rafał Walczak, Kamil Wawrowicz, et al.

    The modular J-PET scanner, comprising 24 compact and versatile modules, each consisting of 13 plastic strips with four SiPM detectors at the ends, represents a powerful tool for clinical applications in nuclear medical imaging. This study presents preliminary results from the exploration of simultaneous dual-isotope imaging using the modular J-PET system. Our approach involved two isotopes: 68Ge, characterized by a ringlike shape, and 22Na, exhibiting a point-like shape. The imaging was based on double-coincidence and triple-coincidence events. In the double coincidence case, both isotopes contributed comparably, whereas in the triple coincidence case 22Na dominated due to the prompt gamma being emitted with 100% of positron emissions, unlike 68Ga, where the prompt gamma was emitted in only 1.3% of cases after positron emission. In this work we present direct 2γ images determined for two-signal events and images for three-signal events, with two signals from annihilation photons and one from a prompt gamma. These results showcase the preliminary findings from simultaneous dual-isotope imaging of 68Ga and 22Na isotopes using the modular J-PET scanner, which will be presented and discussed.


  • Challenging production of Auger electron emitter platinum-195m via double-neutron capture activation of an iridium-193 target

    by Kamil Wawrowicz, Aleksander Bilewicz

    Targeted Auger electron (AE) therapy exhibits great potency against small tumors and metastatic sites, which to date have no effective therapeutic options. However, the development of AE-based therapy is significantly limited due to the low availability of the most promising radionuclides, being the consequence of the poor cognition of relevant nuclear pathways and insufficient accessibility of highly enriched target materials and specific infrastructure. Therefore, the development and investigation approaches to overcome this limitation are highly complex and challenging. In the present paper, as a second group worldwide, we perform experimental evaluation of double-neutron capture of a 195mPt production – radionuclide showing the most favourable characteristics for targeted Auger electron therapy. For this purpose we investigated two-step iridium target activation via 193Ir(n,γ)194Ir(n,γ)195mIr(β-)➝195mPt. In presenting the current state of knowledge of identified production methods of this radionuclide, we highlight the limitations and challenges of cyclotron- and reactor-based approaches. With theoretical calculations followed by short-time irradiation with thermal neutron flux, we describe numerous nuclear and chemical difficulties associated with an investigated nuclear pathway. Obtained results reveal that research and commercial application of this method is significantly hindered or even impossible at the current state of knowledge. We point out the most critical limitations which need to be addressed for further consideration of the mentioned strategy. Therefore, 195mPt application for targeted Auger therapy still remains challenging and requires efforts to overcome the limitations.


  • Open Access

    Platinum nanoparticles labelled with iodine-125 for combined “chemo-Auger electron” therapy of hepatocellular carcinoma

    by Kamil Wawrowicz, Kinga Żelechowska-Matysiak, Agnieszka Majkowska-Pilip, Mateusz Wierzbicki, Aleksander Bilewicz

    Here we present for the first time iodine-125 labeled platinum nanoparticles targeting the tumor microenvironment for combined “chemo-Auger electron” therapy of hepatocellular carcinoma.


  • Open Access

    198Au-Coated Superparamagnetic Iron Oxide Nanoparticles for Dual Magnetic Hyperthermia and Radionuclide Therapy of Hepatocellular Carcinoma

    by Nasrin Abbasi Gharibkandi, Michał Żuk, Fazilet Zumrut Biber Muftuler, Kamil Wawrowicz, Kinga Żelechowska-Matysiak, Aleksander Bilewicz

    This study was performed to synthesize a radiopharmaceutical designed for multimodal hepatocellular carcinoma (HCC) treatment involving radionuclide therapy and magnetic hyperthermia. To achieve this goal, the superparamagnetic iron oxide (magnetite) nanoparticles (SPIONs) were covered with a layer of radioactive gold (198Au) creating core–shell nanoparticles (SPION@Au). The synthesized SPION@Au nanoparticles exhibited superparamagnetic properties with a saturation magnetization of 50 emu/g, which is lower than reported for uncoated SPIONs (83 emu/g). Nevertheless, the SPION@Au core–shell nanoparticles showed a sufficiently high saturation magnetization value which allows them to reach a temperature of 43 °C at a magnetic field frequency of 386 kHz. The cytotoxic effect of nonradioactive and radioactive SPION@Au–polyethylene glycol (PEG) bioconjugates was carried out by treating HepG2 cells with various concentrations (1.25–100.00 µg/mL) of the compound and radioactivity in range of 1.25–20 MBq/mL. The moderate cytotoxic effect of nonradioactive SPION@Au-PEG bioconjugates on HepG2 was observed. The cytotoxic effect associated with the β− radiation emitted by 198Au was much greater and already reaches a cell survival fraction below 8% for 2.5 MBq/mL of radioactivity after 72 h. Thus, the killing of HepG2 cells in HCC therapy should be possible due to the combination of the heat-generating properties of the SPION-198Au–PEG conjugates and the radiotoxicity of the radiation emitted by 198Au.


  • Open Access

    Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers

    by Kinga Żelechowska-Matysiak, Kamil Wawrowicz, Mateusz Wierzbicki, Tadeusz Budlewski, Aleksander Bilewicz, Agnieszka Majkowska-Pilip

    Recently, targeted nanoparticles (NPs) have attracted much attention in cancer treatment due to their high potential as carriers for drug delivery. In this article, we present a novel bioconjugate (DOX–AuNPs–Tmab) consisting of gold nanoparticles (AuNPs, 30 nm) attached to chemotherapeutic agent doxorubicin (DOX) and a monoclonal antibody, trastuzumab (Tmab), which exhibited specific binding to HER2 receptors. The size and shape of synthesized AuNPs, as well as their surface modification, were analyzed by the TEM (transmission electron microscopy) and DLS (dynamic light scattering) methods. Biological studies were performed on the SKOV-3 cell line (HER2+) and showed high specificity of binding to the receptors and internalization capabilities, whereas MDA-MB-231 cells (HER2−) did not. Cytotoxicity experiments revealed a decrease in the metabolic activity of cancer cells and surface area reduction of spheroids treated with DOX–AuNPs–Tmab. The bioconjugate induced mainly cell cycle G2/M-phase arrest and late apoptosis. Our results suggest that DOX–AuNPs–Tmab has great potential for targeted therapy of HER2-positive tumors.


  • Open Access

    Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application

    by Perihan Ünak, Volkan Yasakçı, Elif Tutun, K. Buşra Karatay, Rafał Walczak, Kamil Wawrowicz, Kinga Żelechowska-Matysiak, Agnieszka Majkowska-Pilip, Aleksander Bilewicz

    This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, superparamagnetic iron oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a size from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity toward the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.


  • Open Access

    Multimodal Radiobioconjugates of Magnetic Nanoparticles Labeled with 44Sc and 47Sc for Theranostic Application

    by Perihan Unak, Volkan Yasakçı, Elif Tutun, K. Buşra Karatay, Rafał Walczak, Kamil Wawrowicz, Kinga Żelechowska-Matysiak, Agnieszka Majkowska-Pilip, Aleksander Bilewicz

    This study was performed to synthesize multimodal radiopharmaceutical designed for the diagnosis and treatment of prostate cancer. To achieve this goal, Super Paramagnetic Iron Oxide (SPIO) nanoparticles were used as a platform for targeting molecule (PSMA-617) and for complexation of two scandium radionuclides, 44Sc for PET imaging and 47Sc for radionuclide therapy. TEM and XPS images showed that the Fe3O4 NPs have a uniform cubic shape and a diameter from 38 to 50 nm. The Fe3O4 core are surrounded by SiO2 and an organic layer. The saturation magnetization of the SPION core was 60 emu/g. However, coating the SPIONs with silica and polyglycerol reduces the magnetization significantly. The obtained bioconjugates were labeled with 44Sc and 47Sc, with a yield higher than 97%. The radiobioconjugate exhibited high affinity and cytotoxicity towards the human prostate cancer LNCaP (PSMA+) cell line, much higher than for PC-3 (PSMA-) cells. High cytotoxicity of the radiobioconjugate was confirmed by radiotoxicity studies on LNCaP 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.


  • Open Access

    Oxidative Status as an Attribute for Selective Antitumor Activity of Platinum-Containing Nanoparticles against Hepatocellular Carcinoma

    by Kamil Wawrowicz, Agnieszka Majkowska-Pilip, Marzena Szwed, Kinga Żelechowska-Matysiak, Ewelina Chajduk, Aleksander Bilewicz

    Overcoming the limitations for efficient and selective drug delivery is one of the most challenging obstacles for newly designed anticancer agents. In this study, we present two types of platinum-based nanoparticles (NP), ultrasmall 2 nm PtNPs and core-shell 30 nm Au@Pt, which can be highly cytotoxic in an oxidative environment and remain biologically inactive in cells with lower oxidative status. Our research highlighted the differences in platinum nanoparticle-induced chemotoxicity and is the first study examining its mechanism as a substantial aspect of Au@Pt/PtNPs biological activity. Selectively induced oxidative stress was found to be a primary trigger of NPs’ toxicity. Significant differences between Au@Pt and PtNPs were observed especially during 24 h treatment, due to successful intranuclear PtNPs location (~13% of internalized fraction). Reactive oxygen species (ROS)-level induced from both NPs types were similar, while reduction of reduced glutathione (GSH) intracellular content was stronger after treatment with PtNPs. Any biological activity was found in HER2+ breast cancer cells, which have only slightly increased oxidative status. Platinum-containing nanoparticles are an interesting tool for the improvement of selectivity in anticancer therapies against hepatocellular carcinoma (HCC). Due to intranuclear uptake, 2 nm PtNPs seems to be more promising for further research for HCC therapy.


  • Open Access

    Nanostructures as Radionuclide Carriers in Auger Electron Therapy

    by Nasrin Abbasi Gharibkandi, Joanna Gierałtowska, Kamil Wawrowicz, Aleksander Bilewicz

    The concept of nanoparticle-mediated radionuclide delivery in the cancer treatment has been widely discussed in the past decade. In particular, the use of inorganic and organic nanostructures in the development of radiopharmaceuticals enables the delivery of medically important radioisotopes for radionuclide therapy. In this review, we present the development of nanostructures for cancer therapy with Auger electron radionuclides. Following that, different types of nanoconstructs that can be used as carriers for Auger electron emitters, design principles, nanoparticle materials, and target vectors that overcame the main difficulties are described. In addition, systems in which high-Z element nanoparticles are used as radionuclide carriers, causing the emission of photoelectrons from the nanoparticle surface, are presented. Finally, future research opportunities in the field are discussed as well as issues that must be addressed before nanoparticle-based Auger electron radionuclide therapy can be transferred to clinical use.


  • Open Access

    Degradation of Selected Antidepressants Sertraline and Citalopram in Ultrapure Water and Surface Water Using Gamma Radiation

    by Anna Bojanowska-Czajka, Marta Pyszynska, Agnieszka Majkowska-Pilip, Kamil Wawrowicz

    Gamma radiation was applied to degradation selected antidepressants in ultrapure water and surface water. Additionally, the influence of typical radical scavengers like carbonate, nitrate and humic acid was determined. The cytotoxicity towards liver cells HepG2 and colon cells Caco2 were measured during the radiation process. It was found that radiation technology, specifically ionizing radiation, can achieve satisfactory degradation efficiency with both SER and CIT. It was shown that the process of decomposition of the tested antidepressants with the highest efficiency occurs in the reaction with the hydroxyl radical.